Zinc promotes clot stability by accelerating clot formation and modifying fibrin structure.
Zinc released from activated platelets binds fibrin(ogen) and attenuates fibrinolysis. Although zinc also affects clot formation, the mechanism and consequences are poorly understood. To address these gaps, the effect of zinc on clot formation and structure was examined in the absence or presence of factor (F) XIII. Zinc accelerated a) plasma clotting by 1.4-fold, b) fibrinogen clotting by 3.5- and 2.3-fold in the absence or presence of FXIII, respectively, c) fragment X clotting by 1.3-fold, and d) polymerisation of fibrin monomers generated with thrombin or batroxobin by 2.5- and 1.8-fold, respectively. Whereas absorbance increased up to 3.3-fold when fibrinogen was clotted in the presence of zinc, absorbance of fragment X clots was unaffected by zinc, consistent with reports that zinc binds to the αC-domain of fibrin(ogen). Scanning electron microscopic analysis revealed a two-fold increase in fibre diameter in the presence of zinc and in permeability studies, zinc increased clot porosity by 30-fold with or without FXIII. Whereas FXIII increased clot stiffness from 128 ± 19 Pa to 415 ± 27 Pa in rheological analyses, zinc reduced clot stiffness by 10- and 8.5-fold in the absence and presence of FXIII, respectively. Clots formed in the presence of zinc were more stable and resisted rupture with or without FXIII. Therefore, zinc accelerates clotting and reduces fibrin clot stiffness in a FXIII-independent manner, suggesting that zinc may work in concert with FXIII to modulate clot strength and stability.
Sara J
SJ
Henderson
Jing
J
Xia
Huayin
H
Wu
Alan R
AR
Stafford
Beverly A
BA
Leslie
James C
JC
Fredenburgh
David A
DA
Weitz
Jeffrey I. Weitz, Thrombosis and Atherosclerosis Research Institute, 237 Barton Street East, Hamilton, ON, L8L 2X2, Canada, Tel.: +1 905 521 2100 ext. 40721, E-mail: weitzj@taari.ca.
Jeffrey I
JI
Weitz
D012103:Batroxobin / Q000737:chemistry; D001665:Binding Sites; D001777:Blood Coagulation / Q000187:drug effects*; D003029:Coagulants / Q000737:chemistry; D004305:Dose-Response Relationship, Drug; D005176:Factor XIII / Q000737:chemistry; D005337:Fibrin / Q000737:chemistry*; D005338:Fibrin Fibrinogen Degradation Products / Q000737:chemistry; D005340:Fibrinogen / Q000737:chemistry; D005342:Fibrinolysis; D006801:Humans; D008855:Microscopy, Electron, Scanning; D011108:Polymers / Q000737:chemistry; D000072417:Protein Domains; D012212:Rheology; D013917:Thrombin / Q000737:chemistry; D013997:Time Factors; D015032:Zinc / Q000737:chemistry*
D003029:Coagulants; D005338:Fibrin Fibrinogen Degradation Products; D011108:Polymers; C011468:fibrinmonomer; C030568:fibrinogen fragment X; D005337:Fibrin; D005340:Fibrinogen; D005176:Factor XIII; D012103:Batroxobin; D013917:Thrombin; D015032:Zinc
FXIII; Zinc; clot structure; fibrin; fibrinogen